Iron Induces Cell Death and Strengthens the Efficacy of Antiandrogen Therapy in Prostate Cancer Models
- 1 December 2020
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 26 (23), 6387-6398
- https://doi.org/10.1158/1078-0432.ccr-20-3182
Abstract
Purpose: In search of novel strategies to improve the outcome of advanced prostate cancer (PCa), we considered that PCa cells rearrange iron homeostasis, favoring iron uptake and proliferation. We exploited this adaptation by exposing PCa preclinical models to high-dose iron to induce toxicity and disrupt adaptation to androgen starvation. Experimental Design: We analyzed markers of cell viability and mechanisms underlying iron toxicity in androgen receptor-positive VCaP and LNCaP, castration-resistant DU-145 and PC-3, and murine TRAMP-C2 cells treated with iron and/or the anti-androgen bicalutamide. We validated the results in vivo in VCaP and PC-3 xenografts and in TRAMP-C2 injected mice treated with iron and/or bicalutamide. Results: Iron was toxic for all PCa cells. In particular, VCaP, LNCaP and TRAMP-C2 were highly iron-sensitive. Toxicity was mediated by oxidative stress, which primarily affected lipids, promoting ferroptosis. In highly sensitive cells, iron additionally caused protein damage. High-basal iron content and oxidative status defined high iron-sensitivity. Bicalutamide-iron combination exacerbated oxidative damage and cell death, triggering protein oxidation also in poorly iron-sensitive DU-145 and PC-3 cells. In vivo, iron reduced tumor growth in TRAMP-C2 and VCaP mice. In PC-3 xenografts, bicalutamide-iron combination caused protein oxidation and successfully impaired tumor expansion while single compounds were ineffective. Macrophages influenced body iron distribution but did not limit the iron effect on tumor expansion. Conclusions: Our models allow us to dissect the direct iron effect on cancer cells. We demonstrate the proof of principle that iron toxicity inhibits PCa cell proliferation, proposing a novel tool to strengthen anti-androgen treatment efficacy.Keywords
Other Versions
Funding Information
- Italian Association for Cancer Research (9965)
- AIRC (IG-16807)
This publication has 38 references indexed in Scilit:
- Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100 (Enzalutamide) or Casodex (Bicalutamide) leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signalingCell Death & Disease, 2013
- Iron increases the susceptibility of multiple myeloma cells to bortezomibHaematologica, 2012
- Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemiaAnnals of Oncology, 2012
- Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell DeathCell, 2012
- An Iron Regulatory Gene Signature Predicts Outcome in Breast CancerCancer Research, 2011
- Hypoxia and the metabolic phenotype of prostate cancer cellsBiochimica et Biophysica Acta (BBA) - Bioenergetics, 2009
- Characterization of the cancer chemopreventive NRF2-dependent gene battery in human keratinocytes: demonstration that the KEAP1–NRF2 pathway, and not the BACH1–NRF2 pathway, controls cytoprotection against electrophiles as well as redox-cycling compoundsCarcinogenesis: Integrative Cancer Research, 2009
- Tumour-educated macrophages promote tumour progression and metastasisNature Reviews Cancer, 2004
- The Reactive Oxygen Species- and Michael Acceptor-inducible Human Aldo-Keto Reductase AKR1C1 Reduces the α,β-Unsaturated Aldehyde 4-Hydroxy-2-nonenal to 1,4-Dihydroxy-2-noneneOnline Journal of Public Health Informatics, 2001
- Development of an immunoassay for all human isoferritins, and its application to serum ferritin evaluationClinica Chimica Acta; International Journal of Clinical Chemistry, 1989